25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
On December 20, 2019, federal legislation approving spending limits for the 2020 fiscal year was sig...
Read More >
The outbreak of the novel coronavirus disease 2019 (COVID-19) and the uncertainty surrounding its lo...
Read More >
The National Labor Relations Board (“NLRB”) has been busy this December. It has issued a new rule ...
Read More >
At a news conference on April 20, Governor Wolf announced he is extending his stay-at-home order unt...
Read More >
James D. Rosener, partner in the Commercial Department of Pepper and head of the firm's Internationa...
Read More >
Hot on the heels of the £20 million fine issued to British Airways, the Information Commissioner’s ...
Read More >